FDA Aims To Improve Medical Device Security
The agency has issued proposed draft recommendations to guide incorporation of cybersecurity protections into medical devices at the time of manufacture.
The agency has issued proposed draft recommendations to guide incorporation of cybersecurity protections into medical devices at the time of manufacture.
This action was in response to an executive order issued on August 6, 2020 aimed at protecting the public against outbreaks of emerging diseases and chemical, biological, radiological, and nuclear threats.
The FDA has revoked the emergency use authorization for chloroquine phosphate and hydroxychloroquine sulfate based on emerging data suggesting that these agents are unlikely to be effective against COVID-19.
Substituting 12 single-enantiomer drugs with their racemic precursors had the potential to result in $16.6 billion of savings, with Medicare beneficiaries potentially saving $1.1 billion in out-of-pocket expense.
The US Food and Drug Administration is seeking feedback from healthcare professionals on its proposal to offer fixed-quantity blister packaging for a select number of opioid medications.
The U.S. Food and Drug Administration is launching on April 25, 2019, its “Remove the Risk” campaign, aimed at promoting the safe disposal of unused opioids.
According to the FDA, no data are available to establish the validity of these tests for their intended uses.
Drug overdoses resulted in approximately 72,000 deaths in the US, according to the CDC.
Enzyvant announced that the Food and Drug Administration (FDA) has granted RVT-801 both Rare Pediatric Disease and Fast Track designations for Farber disease.
Nutra Pharma Corp. claims that their unapproved homeopathic products can treat addiction and chronic pain from serious conditions such as cancer, diabetes, shingles, and fibromyalgia.